V1bio is a biotechnology company that was founded with the objective of creating a healthy and valuable one-health ecosystem and revolutionizing the lives of patients worldwide through innovative microbiome therapies. In pursuit of this goal, the company is actively engaged in the research and development of a range of immune and anti-cancer treatments as well as animal health nutrition products using one-health microbiomes. These treatments have the potential to significantly improve the lives of individuals and animals suffering from various diseases and conditions that affect the immune system. V1bio is committed to utilizing cutting-edge technology and research to develop groundbreaking treatments that have the power to transform the lives of patients globally.
' Top-tier microbiome biotechnology company '
We are dedicated to pursuing groundbreaking microbiome to discover and develop medicines
Our mission is to provide the better lives of patients worldwide with revolutionary One Health microbiome and solutions
Respect for people, Act with intergrity
Communication with open-minded
Continuous challenge for innovation
One Health microbiome library
Microbiome profiling (AI & BI)
Multi-omics analysis, Translational research
Live biotherapeutic product
One Health microbiome (human, ainimal)
2022. 10. V1bio-Daewoong Pet MOU to co-operate on microbiome product for companion dog
2022. 08. V1bio-Ahnkook pharm MOU to co-operate on microbiome R&D
2022. 08. Establishment of a research institute (wet-lab)
2022. 08. Selection of TIPA ValueUp program by Korea Technology and Information Promotion Agency for SMEs
2022. 04. Selection of youth employment intern system participating company by the Ministry of Employment and Labor
2022. 03. Selection of KIT family company by the Korea Insitute of Toxicology
2022. 02. Selection of 2022 TIPS program by the Ministry of SMEs and Startups
2021. 12. Selection of K-STARTUP venture post-support program by the Ministry of SMEs and Startups
2021. 12. Certification of the company-affiliated research institute
2021. 11. Seed funding by the DAEWOONG Pharmaceuticals
2021. 11. Certification of the venture company
2021. 09. Seed funding by the Schmidt
2021. 05. Establishment of V1bio Inc
Happy New Year!
We hope that this new year brings you health, prosperity, and success. Thank you for your continued support and partnership. We look forward to working with you in the year ahead and achieving even greater things together. Wishing you all the best in the new year.
At V1bio Inc, we are dedicated to pushing the limits of what is possible in the field of One-Health microbiome research and to making a meaningful impact on the world.
Wishing you all the best in the new year,
ILHWAN KIM, CEO, V1bio Inc